Tags: Repurposing

blog

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers

ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.

announcements

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer's and FTD

A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

blog

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

announcements

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."

announcements

Grantees at Lou Rovo Center for Brain Health Recruiting for New Alzheimer's Disease Trial

Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.

announcements

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.

announcements

Leading Foundations Publish Recommendations to Accelerate Drug Repurposing

A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.

blog

An Alzheimer's Treatment in Your Medicine Cabinet?

A recent New York Times Op-Ed highlights that, while it's possible to "repurpose" available drugs to treat patients, we don't test them because "no one stands to make money." 

blog

Will the First Alzheimer's Treatment Be a Repurposed Drug?

Dr. Jeffrey Cummings, director of the Lou Ruvo Center for Brain Health, talks about the promise repurposed drugs offer to people with Alzheimer's and other dementias.

announcements

Alzheimer’s Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer’s

The ADDF raised more than $1.1 million at its Eighth Annual Connoisseur's Dinner to go to Jeffrey Cummings, MD in support of a clinical trial for a repurposed drug for treating Alzheimer's disease.